Eosinophil-mediated signalling attenuates inflammatory responses in experimental colitis

Gut

Volumn 64, Issue 8, 2015, Pages 1236-1247

  Masterson, Joanne C ^a,b   McNamee, Eóin N ^b   Fillon, Sophie A ^a,b   Hosford, Lindsay ^a,b   Harris, Rachel ^a,b   Fernando, Shahan D ^a,b   Jedlicka, Paul ^b   Iwamoto, Ryo ^c   Jacobsen, Elizabeth ^d,e   Protheroe, Cheryl ^d,e   Eltzschig, Holger K ^b   Colgan, Sean P ^b   Arita, Makoto ^c,d   Lee, James J ^e   Furuta, Glenn T ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d Institute of Physical and Chemical Research   (Japan)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; DEXTRAN SULFATE; DOCOSAHEXAENOIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; OXAZOLONE; PROTECTIN D1; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL MIGRATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; EOSINOPHIL; EXPERIMENTAL COLITIS; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; LIPID ANALYSIS; MASS SPECTROMETRY; MOUSE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; C57BL MOUSE; COLITIS; DISEASE MODEL; IMMUNOLOGY; INTESTINE MUCOSA; MALE; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; DISEASE MODELS, ANIMAL; EOSINOPHILS; INFLAMMATION; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL;

EID: 84940107073     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-306998     Document Type: Article

References (58)

1. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006;24:147-74.
2. Hogan SP, Waddell A, Fulkerson PC. Eosinophils in infection and intestinal immunity. Curr Opin Gastroenterol 2013;29:7-14.
3. Boyce JA, Bochner B, Finkelman FD, et al. Advances in mechanisms of asthma, allergy, and immunology in 2011. J Allergy Clin Immunol 2012;129:335-41.
4. Jacobsen EA, Ochkur SI, Lee NA, et al. Eosinophils and asthma. Curr Allergy Asthma Rep 2007;7:18-26.
5. Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008;38:709-50.
6. Wedemeyer J, Vosskuhl K. Role of gastrointestinal eosinophils in inflammatory bowel disease and intestinal tumours. Best Pract Res Clin Gastroenterol 2008;22:537-49.
7. Hogan SP. Functional role of eosinophils in gastrointestinal inflammation. Immunol Allergy Clin North Am 2009;29:129-40, xi.
8. Masterson JC, Furuta GT, Lee JJ. Update on clinical and immunological features of eosinophilic gastrointestinal diseases. Curr Opin Gastroenterol 2011;27:515-22.
9. Ahrens R, Waddell A, Seidu L, et al. Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol 2008;181:7390-9.
10. Furuta GT, Nieuwenhuis EE, Karhausen J, et al. Eosinophils alter colonic epithelial barrier function: role for major basic protein. Am J Physiol Gastrointest Liver Physiol 2005;289:G890-7.
11. Masterson JC, McNamee EN, Jedlicka P, et al. CCR3 blockade attenuates eosinophilic ileitis and associated remodeling. Am J Pathol 2011;179:2302-14.
12. Arita M. Mediator lipidomics in acute inflammation and resolution. J Biochem 2012;152:313-19.
13. Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta 2010;1801:1260-73.
14. Hudert CA, Weylandt KH, Lu Y, et al. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 2006;103:11276-81.
15. Sakamoto N, Kono S, Wakai K, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 2005;11:154-63.
16. Shoda R, Matsueda K, Yamato S, et al. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr 1996;63:741-5.
17. Bento AF, Claudino RF, Dutra RC, et al. Omega-3 fatty acid-derived mediators 17 (R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol 2011;187:1957-69.
18. Ibrahim A, Mbodji K, Hassan A, et al. Anti-inflammatory and anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium. Clin Nutr 2011;30:678-87.
19. Matsunaga H, Hokari R, Kurihara C, et al. Omega-3 polyunsaturated fatty acids ameliorate the severity of ileitis in the senescence accelerated mice (SAM) P1/Yit mice model. Clin Exp Immunol 2009;158:325-33.
20. Varma S, Eskin MN, Bird R, et al. Potential of magnetic resonance spectroscopy in assessing the effect of fatty acids on inflammatory bowel disease in an animal model. Lipids 2010;45:843-54.
21. Kuhn H, O'Donnell VB. Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res 2006;45:334-56.
22. Levy BD, Kohli P, Gotlinger K, et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007;178:496-502.
23. Serhan CN, Gotlinger K, Hong S, et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol 2006;176:1848-59.
24. Yamada T, Tani Y, Nakanishi H, et al. Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice. FASEB J 2011;25:561-8.
25. Isobe Y, Kato T, Arita M. Emerging roles of eosinophils and eosinophil-derived lipid mediators in the resolution of inflammation. Front Immunol 2012;3:270.
26. Marcheselli VL, Mukherjee PK, Arita M, et al. Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot Essent Fatty Acids 2010;82:27-34.
27. Lee JJ, Dimina D, Macias MP, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004;305:1773-6.
28. Smith P, Mangan NE, Walsh CM, et al. Infection with a helminth parasite prevents experimental colitis via a macrophage-mediated mechanism. J Immunol 2007;178:4557-66.
29. Chen P, Fenet B, Michaud S, et al. Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation. FEBS Lett 2009;583:3478-84.
30. McNamee EN, Masterson JC, Jedlicka P, et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA 2011;108:16711-16.
31. Protheroe C, Woodruff SA, De Petris G, et al. A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2009;7:749-55. e11.
32. Masterson JC, McNamee EN, Hosford L, et al. Local hypersensitivity reaction in transgenic mice with squamous epithelial IL-5 overexpression provides a novel model of eosinophilic oesophagitis. Gut 2014;63:43-53.
33. Furuta GT, Ackerman SJ, Lu L, et al. Stem cell factor influences mast cell mediator release in response to eosinophil-derived granule major basic protein. Blood 1998;92:1055-61.
34. Aherne CM, Collins CB, Masterson JC, et al. Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis. Gut 2012;61:695-705.
35. Colgan SP, Dzus AL, Parkos CA. Epithelial exposure to hypoxia modulates neutrophil transepithelial migration. J Exp Med 1996;184:1003-15.
36. Schwab JM, Chiang N, Arita M, et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007;447:869-74.
37. Miyata J, Fukunaga K, Iwamoto R, et al. Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma. J Allergy Clin Immunol 2013;131:353-60. e2.
38. Woodruff SA, Masterson JC, Fillon S, et al. Role of eosinophils in inflammatory bowel and gastrointestinal diseases. J Pediatr Gastroenterol Nutr 2011;52:650-61.
39. Forbes E, Murase T, Yang M, et al. Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase. J Immunol 2004;172:5664-75.
40. Forbes E, Hulett M, Ahrens R, et al. ICAM-1-dependent pathways regulate colonic eosinophilic inflammation. J Leukoc Biol 2006;80:330-41.
41. Stevceva L, Pavli P, Husband A, et al. Eosinophilia is attenuated in experimental colitis induced in IL-5 deficient mice. Genes Immun 2000;1:213-18.
42. Chu VT, Frohlich A, Steinhauser G, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nature immunology 2011;12:151-9.
43. Chu VT, Beller A, Rausch S, et al. Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity 2014;40:582-93.
44. Specht S, Arriens S, Hoerauf A. Induction of chronic colitis in IL-10 deficient mice requires IL-4. Microbes Infect 2006;8:694-703.
45. Stasikowska-Kanicka O, Danilewicz M, Glowacka A, et al. Mast cells and eosinophils are involved in activation of ulcerative colitis. Adv Med Sci 2012;57:230-6.
46. Lampinen M, Ronnblom A, Amin K, et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 2005;54:1714-20.
47. Vieira AT, Fagundes CT, Alessandri AL, et al. Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. Am J Pathol 2009;175:2382-91.
48. Nei Y, Obata-Ninomiya K, Tsutsui H, et al. GATA-1 regulates the generation and function of basophils. Proc Natl Acad Sci USA 2013;110:18620-5.
49. Jacobsen EA, Lesuer WE, Willetts L, et al. Eosinophil Activities Modulate the Immune/Inflammatory Character of Allergic Respiratory Responses in Mice. Allergy 2014;69(3):315-27.
50. Ma BW, Bokulich NA, Castillo PA, et al. Routine habitat change: a source of unrecognized transient alteration of intestinal microbiota in laboratory mice. PLoS ONE 2012;7:e47416.
51. Kromann N, Green A. Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med Scand 1980;208:401-6.
52. Hillier K, Jewell R, Dorrell L, et al. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991;32:1151-5.
53. Katz MS, Thatch KA, Schwartz MZ. Hepatocyte growth factor and omega-3-enriched feeds have a synergistic effect on mucosal mass in an animal model of inflammatory bowel disease. J Pediatr Surg 2012;47:194-8.
54. Ajuebor MN, Singh A, Wallace JL. Cyclooxygenase-2-derived prostaglandin D (2) is an early anti-inflammatory signal in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2000;279:G238-44.
55. O'Flaherty JT, Thomas MJ. Effect of 15-lipoxygenase-derived arachidonate metabolites on human neutrophil degranulation. Prostaglandins Leukot Med 1985;17:199-212.
56. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003;278:43807-17.
57. Campbell EL, Bruyninckx WJ, Kelly CJ, et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity 2014;40:66-77.
58. Kuhl AA, Kakirman H, Janotta M, et al. Aggravation of different types of experimental colitis by depletion or adhesion blockade of neutrophils. Gastroenterology 2007;133:1882-92.